|
gptkbp:instanceOf
|
gptkb:Company
|
|
gptkbp:acquisition
|
gptkb:Ranbaxy_Laboratories
|
|
gptkbp:advertising
|
gptkb:Mr._Hiroshi_Yamamoto
|
|
gptkbp:awards
|
gptkb:Top_Employer_Japan
Pharma Innovation Awards
Best_Workplaces_in_Asia
Global_Health_&_Pharma_Awards
|
|
gptkbp:CEO
|
gptkb:Seigo_Kikuchi
|
|
gptkbp:clinicalTrials
|
ongoing
collaborative studies
patient-centered research
real-world evidence studies
biomarker_studies
|
|
gptkbp:community_engagement
|
disaster relief efforts
health education programs
volunteer programs
partnerships with NGOs
support for local health initiatives
|
|
gptkbp:employees
|
approximately 15,000
|
|
gptkbp:founded
|
2005
|
|
gptkbp:founder
|
gptkb:Daiichi_Pharmaceutical
|
|
gptkbp:global_presence
|
over 20 countries
|
|
gptkbp:headquarters
|
gptkb:Tokyo,_Japan
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Daiichi Sankyo Company, Limited
|
|
gptkbp:industry
|
pharmaceuticals
|
|
gptkbp:innovation
|
biotechnology
precision medicine
digital health solutions
drug_discovery
|
|
gptkbp:market
|
global
|
|
gptkbp:partnerships
|
gptkb:AstraZeneca
gptkb:Boehringer_Ingelheim
gptkb:Eisai_Co.,_Ltd.
gptkb:Pfizer
|
|
gptkbp:philanthropy
|
gptkb:Daiichi_Sankyo_Foundation_of_Life_Science
|
|
gptkbp:products
|
antibiotics
vaccines
oncology drugs
|
|
gptkbp:research
|
Dr. Masato Saito
|
|
gptkbp:researchAndDevelopment
|
oncology
immunology
cardiovascular
|
|
gptkbp:revenue
|
$9.5 billion (2020)
|
|
gptkbp:stockExchange
|
gptkb:Tokyo_Stock_Exchange
4568
|
|
gptkbp:subsidiary
|
gptkb:Daiichi_Sankyo,_Inc.
|
|
gptkbp:sustainability
|
environmental initiatives
social responsibility
governance practices
|
|
gptkbp:type
|
public company
|
|
gptkbp:website
|
www.daiichisankyo.com
|